Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 7/20 | 0.51 |
| ▸ | MMP2 | P08253 | 7/20 | 0.48 |
| ▸ | MMP3 | P08254 | 6/20 | 0.48 |
| ▸ | MMP1 | P03956 | 5/20 | 0.48 |
| ▸ | MMP13 | P45452 | 3/20 | 0.48 |
| ▸ | MMP7 | P09237 | 3/20 | 0.48 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.48 |
| ▸ | TARS1 | P26639 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1108540 | 0.91 | PGR (0.42) | MMP9MMP2MMP3MMP1MMP13 | |
| SCHEMBL1108567 | 0.91 | MMP2 (0.43) | MMP9MMP2MMP3MMP1MMP13 | |
| SCHEMBL1108539 | 0.91 | FFAR1 (0.42) | MMP9MMP2MMP3MMP1MMP13 | |
| SCHEMBL1108478 | 0.89 | MMP1 (0.41) | MMP9MMP2MMP3MMP1MMP13 | |
| SCHEMBL1108533 | 0.89 | FFAR1 (0.41) | MMP9MMP2MMP3MMP1MMP13 | |
| SCHEMBL1108481 | 0.87 | CACNA1H (0.43) | MMP9MMP2MMP3MMP1MMP13 | |
| SCHEMBL1108534 | 0.86 | CACNA1H (0.43) | MMP9MMP2MMP3MMP1MMP13 | |
| SCHEMBL7138393 | 0.86 | MMP9 (0.37) | MMP9MMP2MMP3MMP1MMP13 | |
| SCHEMBL13500326 | 0.86 | ADAMTS4 (0.47) | MMP9MMP2MMP3MMP1MMP13 | |
| SCHEMBL1108574 | 0.81 | ALDH1A1 (0.38) | MMP1ADAMTS4ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153673-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| US-8153673-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| US-20100273849-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | US | disclosed |
| US-20100273849-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | US | disclosed |
| US-7666892-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2010-02-23 | — | — | US | disclosed |
| US-7666892-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2010-02-23 | — | — | US | disclosed |
| US-20080262045-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
| US-20080262045-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
| US-7368465-B2 | Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders | ASTRAZENECA AB (SE) | 2008-05-06 | — | — | US | disclosed |
| US-7368465-B2 | Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders | ASTRAZENECA AB (SE) | 2008-05-06 | — | — | US | disclosed |
| US-20040138276-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | disclosed |
| US-20040138276-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273849-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP11 | MMP9 1/4885MMP2 9/4885MMP3 5/4885 |
| US-20080262045-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP11 | MMP9 1/4885MMP2 9/4885MMP3 5/4885 |
| US-20040138276-A1 | Metalloproteinase inhibitors | MMP9, MMP11, MMP7 | MMP9 1/4885MMP2 8/4885MMP3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.